A detailed history of Black Rock Inc. transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 7,288,378 shares of COGT stock, worth $57.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,288,378
Previous 6,689,618 8.95%
Holding current value
$57.3 Million
Previous $45 Million 36.68%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.01 - $9.04 $3.6 Million - $5.41 Million
598,760 Added 8.95%
7,288,378 $61.4 Million
Q1 2024

May 10, 2024

SELL
$4.38 - $9.02 $288,931 - $595,013
-65,966 Reduced 0.98%
6,689,618 $45 Million
Q4 2023

Feb 13, 2024

BUY
$4.06 - $10.08 $2.47 Million - $6.13 Million
608,506 Added 9.9%
6,755,584 $39.7 Million
Q3 2023

Nov 13, 2023

BUY
$9.69 - $13.34 $6.49 Million - $8.93 Million
669,416 Added 12.22%
6,147,078 $59.9 Million
Q2 2023

Aug 11, 2023

BUY
$9.85 - $13.24 $4.29 Million - $5.77 Million
435,592 Added 8.64%
5,477,662 $64.9 Million
Q1 2023

May 12, 2023

BUY
$10.04 - $15.5 $960,095 - $1.48 Million
95,627 Added 1.93%
5,042,070 $54.4 Million
Q4 2022

Feb 13, 2023

BUY
$10.65 - $14.84 $3.73 Million - $5.2 Million
350,140 Added 7.62%
4,946,443 $57.2 Million
Q3 2022

Nov 14, 2022

BUY
$9.39 - $16.99 $12.2 Million - $22.1 Million
1,299,523 Added 39.42%
4,596,303 $68.6 Million
Q2 2022

Aug 12, 2022

BUY
$3.92 - $9.73 $2.58 Million - $6.4 Million
657,409 Added 24.91%
3,296,780 $29.7 Million
Q1 2022

May 12, 2022

SELL
$5.31 - $8.7 $314,792 - $515,762
-59,283 Reduced 2.2%
2,639,371 $19.8 Million
Q4 2021

Feb 10, 2022

SELL
$7.51 - $10.81 $252,193 - $363,010
-33,581 Reduced 1.23%
2,698,654 $23.2 Million
Q3 2021

Nov 09, 2021

BUY
$5.99 - $9.14 $328,533 - $501,301
54,847 Added 2.05%
2,732,235 $23 Million
Q2 2021

Aug 11, 2021

BUY
$7.82 - $9.3 $20.9 Million - $24.9 Million
2,677,388 New
2,677,388 $21.7 Million

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $517M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.